Patients receiving a mechanical circulatory support device (MCSD) place their lives in the hands of the engineers who design the MCSDs and the physicians who manage the MCSDs. From the patient's standpoint, the ideal MCSD would have sufficient durability to sustain their life until they die of something other than heart failure, mechanical pump failure, or a complication of MCSD therapy.
From an engineering and clinical perspective, the reliability or durability is measured by the rate of device failure over time. 1 MCSD failure can be the result of a mechanical problem (eg, drive unit or motor failure of an implanted ventricular assist device [VAD]) or a biologic complication involving the MCSD (eg, device thrombosis or hemolysis). The most devastating failures of durability result in death of the patient. If MCSD failure is not fatal but requires replacement of the implanted components, it exposes the patient to the important risks of death and other adverse events.
In the present study, we analyzed the durability of MCSDs that have been approved by the Federal Food and Drug Administration (FDA) and tracked by the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). 2 Our aim was to define the MCSD failure rates for several modes of failure and to compare the failure rates and modes of failure for the 2 major classes of MCSDs: pulsatile and continuous flow (CF) pumps. The ultimate goals were to (1) stimulate improvements in the engineering of MCSDs; and (2) suggest changes in the clinical treatment of patients to maximize MCSD durability.
METHODS
The INTERMACS is a national registry for patients who receive a MCSD to treat advanced medically refractory heart failure. The INTER-MACS indications for mechanical circulatory support include destination therapy (ie, a long-term MCSD for patients with a contraindication to transplantation), bridge to transplantation, and bridge to recovery of the native heart. Only FDA-approved MCSDs that can be used in an outpatient setting are included in the INTERMACS. 2 A total of 106 institutions were enrolled in the INTERMACS from June 23, 2006 to March 31, 2011, the period of data acquisition for the present study. The data were entered using encryption to a secure server administered by the United Network for Organ Sharing. The United Network for Organ Sharing data repository is accessible to INTERMACS investigators for analysis of patient de-identified information. The study sites and central data processing and analyzing facilities received institutional review board approval before initiating the collection of data. All patients provided informed consent before entry in the INTERMACS. The data were managed according to the Health Insurance Portability and Accountability Act regulations.
During this phase of data acquisition, the MCSDs included in the INTERMACS database included the AbioCor total artificial heart (Abiomed, Danvers, Mass); the HeartMate IP, VE, and XVE left VADs (LVADs; Thoratec, Pleasanton, Calif); the HeartMate II LVAD (Thoratec), the MicroMed DeBakey Child LVAD (MicroMed, Houston, Tex); the Novacor PC and PCq LVADs (Novacor, Oakland, Calif); the SynCardia Cardiowest total artificial heart (Syncardia Systems, Tucson, Ariz); and the Thoratec implantable VAD and paracorporeal VAD pumps (Thoratec, Pleasanton, Calif). 3 The total artificial hearts and paracorporeal VADs were not included in the present analysis. Only adults aged 18 years or older were included in the present study; thus, the MicroMed DeBakey Child LVADs were excluded.
The INTERMACS variables describing the preimplant demographic profile, indication for mechanical circulatory support, and clinical variables that described the preimplant patient condition, hemodynamics, and laboratory values were analyzed to define the risk factors for postoperative device durability. The relevant durability issues included pump replacement for intractable infection, thrombosis-hemolysis, driveline failure, or pump drive unit failure and death from driveline or pump drive unit failure. The patients were censored from the analysis because of transplantation, device removal for recovery, and death not related to pump failure.
The INTERMACS data were checked for completeness by the central collection facility (United Network for Organ Sharing). The data that were outside the predetermined limits were validated by their site of origin; however, the source documents were not routinely checked against the data submitted to the INTERMACS. The adverse event forms were reviewed by physician volunteers from the INTERMACS community and checked further by the members of the INTERMACS adverse event committee before a final adjudication was made on the individual adverse events.
The variables describing the preimplant patient condition, indication for mechanical circulatory support, demographic profile, hemodynamics, laboratory values, and durability issues were gathered. The data were analyzed using a competing outcomes method to identify the risk factors for postoperative pump exchange and death from durability issues. The pulsatile and CF rotary pumps were compared for durability as an aggregate outcome and were compared again according to the individual durability issues specified in the previous paragraphs.
RESULTS
The data for 3302 patients were entered by 106 institutions within the study period, with a follow-up date of March 31, 2011. Pulsatile pumps were approved for clinical use by the Federal FDA before CF pumps; therefore, these 2 groups were nonconcurrent. Of the 3302 LVADs implanted, 486 were pulsatile and 2816 were CF LVADs. The total experience included 2624 patient-years of support and 585 nonpump-related deaths. Also, 100 pump exchanges occurred and 11 deaths from durability issues (59 pulsatile deaths/exchanges and 52 CF deaths/exchanges; Table 1 ). The pumprelated issues that led to exchange or death are listed in Table  E1 , and the interval to device issue (pump exchange or pump-related death) is shown in Figure 1 . The CF devices failed predominantly because of pump thrombosis and hemolysis (28/52 [54% of events]), and the pulsatile pump failed predominantly because of pump drive unit failure (46/59 [78% of events]). The interval to all-cause pump-related failure (death or pump exchange) was significantly (P<.0001) longer for CF pumps than for pulsatile pumps.
The causes for durability failure are depicted individually in Figures 2, 3 , E1, and E2. The durability, as defined by drive unit failure, was significantly better for the CF pumps than the pulsatile pumps (P<.0001; Figure 2 ). The interval to the first driveline problem, thrombosis-hemolysis, or infection that required device exchange was similar for the pulsatile and CF LVADs (Figures 3, E1 , and E2). The competing outcomes analyses for pulsatile and CF pumps ( Figure 4 ) corroborate the greater durability of CF pumps compared with pulsatile pumps. This was evidenced by the greater proportion of CF patients remaining on pump support at 12 months after device implant (54% of 2816 CF implants vs 32% of 486 pulsatile LVADs), although other possible explanations exist for the finding. Other explanations include a greater proportion of patients with panel reactive antibodies or blood group O or a greater number of destination therapy patients than bridge to transplantation patients in the CF group.
DISCUSSION
The concept of durability is of obvious importance to cardiac replacement therapies. In 1998, a joint American Society for Artificial Internal Organs-Society of Thoracic Surgeons committee published recommendations and goals for the development and clinical evaluation of MCSDs. 4 That document defined failure as ''the termination of the most robust information currently available on the outcomes of patients supported by MCSDs. 5, 8 Device durability is extremely important to MCSD patients and their physicians. Device failure for any reason typically requires pump replacement, which adds substantial cost to MCSD therapy, exposes the patient to possible death or morbid events, and diminishes the patient's quality of life. The present report was designed to measure the failure rates for implanted LVADs and to compare these rates between pulsatile and CF pumps.
Time to First Drive Unit Pump Issue
Pulsatile LVADs were represented in the INTERMACS predominantly by the pulsatile HeartMate I (Thoratec). Moreover, the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial used the HeartMate I for the MCSD arm of the study, which compared survival and other outcomes for patients with end-stage heart disease treated with optimal medical management versus mechanical circulatory support using a pump approved by the FDA. 9 That landmark trial demonstrated the superiority of mechanical circulatory support over medical management in patients with severe heart failure; however, it also illustrated the drawbacks of mechanical circulatory support. These included substantial postimplant mortality for LVAD patients at 1 (48%) and 2 (77%) years and a high rate of pump replacement for pump failure 12 to 18 months after implantation.
The Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent (INTrEPID) trial compared the pulsatile Novacor LVAD (WorldHeart, Oakland, Calif) and optimal medical therapy for inotrope-dependent patients with New York Heart Association functional class IV symptoms. The INTrEPID trial was a nonrandomized study that corroborated the superiority of MCSD over medical therapy using a pulsatile LVAD. 10 The patients in the LVAD arm of that study had a 27% 12-month survival, and mechanical failure of the Novacor LVAD was not listed as a cause of death or an adverse event for any patient. In the present trial, cerebrovascular accidents (10/37 patients), infection (7/37 patients), and cardiac dysfunction (5/37 patients) were the most commonly reported causes of death.
The results of clinical trials stimulated design changes in pulsatile pumps that resulted in improved patient outcomes, defined as improved survival with fewer adverse events. 11, 12 However, the disadvantages of pulsatile implantable blood pumps compared with implanted rotary CF pumps (eg, patient acceptance, ease of implantation) resulted in dominance of the field by CF designs. From the data from the present study, the durability of CF pumps compared with pulsatile pumps is an important aspect of the CF pump advantage. The importance of improved durability was noted in the first FDA investigational device exemption trial that compared an axial flow rotary pump to a pulsatile design. 13 The INTERMACS data were used in the present analysis to quantify the improved durability of rotary pumps from experience at multiple centers.
Despite the improved durability of CF LVADs, the present analysis identified problems with the CF designs that led to pump failure, defined as pump-related adverse events causing patient death or requiring pump exchange. Pump thrombosis and pump-related hemolysis were identified in 28 of 52 of these instances (54%), and intractable infection, drive unit failure, and driveline problems were each responsible in 13% to 19% of instances. Importantly, all 4 of these problems are amenable to improvement through design optimization by engineers (eg, improved hemocompatibility of blood contacting materials; diminished turbulence, and shear forces within the pump) or changes in patient treatment (eg, patient-specific anticoagulation 14, 15 ; novel methods for driveline implantation and stabilization; implementation of an intensive surveillance protocol for out-patients 16 ).
The clinical results from previous multicenter randomized 17 and nonrandomized 18 studies corroborate the findings of the present analysis regarding the improved durability of CF LVADs compared with pulsatile LVADs. In a 2009 study by Pagani and colleagues, 18 the 18-month actuarial survival for the HeartMate II LVAD recipients was 72% (95% confidence interval, 65%-79%), and in a 2009 study by Slaughter and colleagues, 19 the 24-month actuarial survival for the HeartMate II LVAD recipients was 58% (95% confidence interval, 49%-67%).
As investigators identify the features of LVADs that limit their useful life, subsequent improvements can be expected that will increase pump durability and patient survival. With these improvements, it can be expected that survival will become equivalent between LVAD therapy and heart transplantation for certain patient groups with advanced heart failure. 19 Furthermore, MCSDs might be routinely used before and after heart transplantation to maximize patient survival through sequential MCSD and transplantation therapies. Data presented as n (%).
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